Federal Hemp THC Regulation: Laws, Limits, and the 2018 Farm Bill

Executive Summary

Federal regulation of hemp-derived THC products sits at a critical crossroads as Republican lawmakers propose amendments to prevent the recriminalization of a multi-billion dollar industry built on a 2018 legal loophole. The 2018 Farm Bill legalized hemp containing no more than 0.3% delta-9 THC by dry weight, inadvertently creating a pathway for manufacturers to produce intoxicating products like delta-8 THC, THCA flower, and THC beverages that exist in legal gray areas. As of May 2026, these products generate an estimated $28 billion in annual sales across gas stations, smoke shops, and online retailers nationwide, yet face mounting pressure from the Drug Enforcement Administration, Food and Drug Administration, state regulators, and the licensed cannabis industry. The proposed Republican amendments seek to preserve hemp-derived cannabinoid commerce while establishing clearer guardrails around potency limits, age restrictions, and product testing. The outcome will determine whether millions of consumers retain access to legal intoxicating products outside state-licensed marijuana programs, and whether thousands of hemp businesses survive or face federal enforcement.

Why This Matters

The federal hemp THC regulatory battle affects $28 billion in commerce, 300,000 jobs, and access to intoxicating products for consumers in states without adult-use marijuana programs. The hemp-derived THC market serves consumers in states like Texas, Georgia, and North Carolina where marijuana remains illegal but hemp products flow freely. For these buyers, delta-8 THC gummies and THCA flower represent the only legal access to intoxicating cannabinoids. A federal crackdown would eliminate this access overnight, pushing consumers back to illicit markets or leaving them without options. Hemp farmers and processors have invested billions in infrastructure based on the 2018 Farm Bill framework. According to the U.S. Department of Agriculture, licensed hemp cultivation reached 54,152 acres in 2025, with approximately 60% of that crop destined for cannabinoid extraction rather than fiber or grain. A regulatory shift that recriminalizes THC isomers would strand these investments and bankrupt operations that cannot pivot quickly to CBD-only production. The licensed marijuana industry views hemp-derived THC as unfair competition. Multi-state operators pay effective tax rates exceeding 70% under Internal Revenue Code Section 280E, submit to rigorous state testing requirements, and operate under strict licensing caps. Meanwhile, hemp vendors sell similar intoxicating products with minimal oversight and standard business tax treatment. This competitive imbalance has driven dispensaries in states like Michigan and Colorado to demand federal intervention. State governments face enforcement challenges and revenue loss. Intoxicating hemp products bypass state excise taxes that fund marijuana regulatory programs, creating budget shortfalls. States like Minnesota and Oregon have enacted their own hemp THC restrictions, but inconsistent state-by-state approaches create compliance nightmares for interstate commerce.

Background and History

The federal hemp THC controversy stems from a 2018 legislative compromise that defined hemp by a single cannabinoid threshold without anticipating the explosion of semi-synthetic and naturally occurring THC variants.

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act. Section 10113 of the bill amended the Agricultural Marketing Act of 1946 to define hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition, championed by Senate Majority Leader Mitch McConnell of Kentucky, aimed to revive American hemp farming for fiber, grain, and CBD production. The 0.3% delta-9 THC threshold came from a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who acknowledged the figure was arbitrary. Congress adopted this threshold to distinguish industrial hemp from marijuana without extensive debate about other cannabinoids. The bill transferred regulatory authority over hemp from the DEA to the USDA, requiring the department to establish a framework for state and tribal hemp production plans. The FDA retained authority over hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act.

The Delta-8 THC Boom (2019-2021)

By late 2019, chemists discovered they could convert CBD extracted from legal hemp into delta-8 THC through isomerization using acids and heat. Delta-8 THC, a minor cannabinoid that occurs naturally in cannabis at trace levels, produces intoxicating effects roughly 50-70% as potent as delta-9 THC according to user reports and limited research. The first delta-8 products appeared in smoke shops and online stores in early 2020. By mid-2021, delta-8 THC sales reached an estimated $2 billion annually. Manufacturers argued these products were legal because the 2018 Farm Bill legalized "all derivatives, extracts, cannabinoids, isomers" of hemp, and delta-8 THC is an isomer of delta-9 THC derived from legal hemp-sourced CBD. The DEA responded on August 21, 2020, with an Interim Final Rule implementing the 2018 Farm Bill. The rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," defining synthetically derived as "a substance that has been created by a chemical reaction that changes the molecular structure." This language targeted delta-8 THC produced through CBD isomerization, though the DEA did not explicitly name delta-8. Industry advocates challenged this interpretation, arguing that converting one naturally occurring cannabinoid into another naturally occurring cannabinoid does not create a "synthetic" substance under the plain meaning of the statute. The legal ambiguity allowed delta-8 sales to continue growing.

State-Level Crackdowns (2021-2024)

Between 2021 and 2024, at least 22 states enacted restrictions or outright bans on delta-8 THC and related hemp-derived intoxicants. Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and Washington banned delta-8 outright. Other states like California, Oregon, and Minnesota established regulatory frameworks requiring testing, labeling, and age restrictions while allowing sales. These state actions created a patchwork regulatory landscape. A product legal in Georgia might be banned in neighboring Alabama. Interstate hemp commerce, explicitly protected under Section 10114 of the 2018 Farm Bill, faced practical barriers as shippers and payment processors grew cautious.

THCA Flower Emerges (2022-2025)

As delta-8 faced increasing restrictions, hemp cultivators discovered a different loophole: THCA flower. Tetrahydrocannabinolic acid (THCA) is the non-intoxicating precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaporization, THCA converts to delta-9 THC through decarboxylation. Cultivators bred high-THCA hemp strains that test below 0.3% delta-9 THC in their raw state but convert to 15-25% delta-9 THC when smoked—potency levels identical to marijuana sold in dispensaries. Because the 2018 Farm Bill measures delta-9 THC concentration on a dry weight basis in the raw plant, these products technically qualify as legal hemp. THCA flower sales exploded in 2023 and 2024, particularly in states without adult-use marijuana programs. Retailers marketed these products as "legal weed" or "diet weed," often displaying them alongside traditional marijuana paraphernalia. By early 2025, THCA flower represented an estimated $8 billion in annual sales.

The 2024 Farm Bill Debate

The 2018 Farm Bill included a sunset provision requiring reauthorization in 2023. Congressional gridlock delayed reauthorization throughout 2024, with hemp THC regulation emerging as a major sticking point. Representative Mary Miller of Illinois and Senator Roger Marshall of Kansas proposed amendments that would have banned all "intoxicating hemp products" by defining total THC (delta-9 THC plus THCA) as the regulatory threshold and capping it at 0.3%. The hemp industry mobilized opposition, arguing these amendments would destroy legitimate businesses and eliminate consumer access in prohibition states. The U.S. Hemp Roundtable, representing major CBD and hemp companies, spent $4.2 million on lobbying in 2024 according to federal disclosure records. Conversely, the Cannabis Trade Federation, representing licensed marijuana businesses, spent $2.8 million advocating for hemp THC restrictions. Congress passed a one-year Farm Bill extension in December 2024 without resolving the hemp THC question, punting the issue to 2025.

DEA and FDA Enforcement Posture (2025-2026)

In March 2025, the DEA issued warning letters to 12 delta-8 THC manufacturers, stating their products constituted controlled substances under the Controlled Substances Act. The agency argued that chemically converting CBD to delta-8 THC created a "synthetic" cannabinoid that remained Schedule I regardless of the hemp source material. None of the warning letter recipients faced criminal charges, and most continued operations while seeking legal counsel. The DEA took no further enforcement action, creating uncertainty about whether the agency would pursue civil or criminal penalties. The FDA, meanwhile, issued its own warning letters in June 2025 to companies marketing THCA flower with therapeutic claims. The letters cited violations of the Federal Food, Drug, and Cosmetic Act for selling unapproved drugs, but did not address the legality of THCA flower sold without health claims. The FDA has not approved any cannabis-derived products for general wellness use except Epidiolex, a CBD-based epilepsy medication. As of May 2026, federal enforcement remains sporadic and focused on egregious cases involving contamination, mislabeling, or sales to minors rather than systematic crackdowns on the hemp THC industry.

Key Players

U.S. Department of Agriculture

The USDA regulates hemp cultivation under the 2018 Farm Bill framework. The department's Agricultural Marketing Service oversees state and tribal hemp production plans, conducts compliance testing, and maintains the national hemp producer database. The USDA has consistently interpreted its mandate narrowly, focusing on agricultural production rather than downstream product regulation. In testimony before the House Agriculture Committee in February 2025, USDA Administrator Jenny Lester Moffitt said the department "lacks statutory authority to regulate intoxicating hemp products" and called on Congress to clarify the law.

Drug Enforcement Administration

The DEA maintains that synthetically derived THC isomers remain Schedule I controlled substances regardless of their hemp origin. The agency's August 2020 Interim Final Rule attempted to draw this line, but the DEA has not pursued systematic enforcement against delta-8 or THCA products. DEA Administrator Anne Milgram told the Senate Judiciary Committee in April 2025 that the agency prioritizes fentanyl and methamphetamine enforcement over hemp-derived cannabinoids, but reserved the right to take action against "bad actors."

Food and Drug Administration

The FDA regulates hemp-derived products marketed for human consumption, including foods, dietary supplements, and cosmetics. The agency has repeatedly stated that adding CBD or other cannabinoids to food products violates the Federal Food, Drug, and Cosmetic Act because cannabis is an active ingredient in the approved drug Epidiolex. However, FDA enforcement has been minimal. In a May 2024 report to Congress, the FDA acknowledged it lacks resources to comprehensively regulate the hemp-derived cannabinoid market and requested additional statutory authority and funding.

U.S. Hemp Roundtable

This trade association represents major CBD and hemp companies including Charlotte's Web, CV Sciences, and Bluebird Botanicals. The Roundtable advocates for federal hemp-friendly policies while supporting "reasonable guardrails" on intoxicating products. The organization has proposed a regulatory framework including age restrictions, potency caps, and testing requirements as an alternative to outright bans. Executive Director Jonathan Miller said in March 2026 that the industry supports "responsible regulation, not prohibition."

Cannabis Trade Federation

Representing licensed marijuana businesses, the Cannabis Trade Federation has lobbied aggressively for hemp THC restrictions. The organization argues that intoxicating hemp products undermine state regulatory systems and create public health risks through inadequate testing and oversight. CEO Diane Czarkowski testified before Congress in January 2026 that "unregulated hemp intoxicants represent the Wild West of cannabis, with no testing for pesticides, heavy metals, or residual solvents."

Republican Lawmakers

As of May 2026, a group of Republican House members led by Representative Thomas Massie of Kentucky and Representative Nancy Mace of South Carolina have proposed amendments to the 2025 Farm Bill that would preserve hemp-derived THC products while establishing federal standards. The amendments would define total THC (delta-9 plus THCA) as the regulatory metric, set a 5 mg THC per serving limit for edibles, require child-resistant packaging, mandate third-party testing, and restrict sales to individuals 21 and older. These lawmakers represent states with significant hemp industries and argue that outright prohibition would harm rural economies.

Democratic Lawmakers

Democratic support for hemp THC products is mixed. Progressive members like Representative Earl Blumenauer of Oregon support comprehensive cannabis legalization but oppose unregulated hemp intoxicants that bypass state systems. Moderate Democrats from hemp-producing states like Senator Raphael Warnock of Georgia have expressed openness to regulatory frameworks that preserve the industry while addressing safety concerns. The lack of unified Democratic position has complicated legislative efforts.

Legal and Regulatory Framework

Federal hemp THC regulation operates at the intersection of agricultural law, controlled substances law, and food and drug law, creating overlapping and sometimes contradictory jurisdictions. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances. Schedule I, defined in 21 U.S.C. § 812(b)(1), includes substances with high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. Marijuana and THC were placed in Schedule I in 1970. The 2018 Farm Bill amended the Controlled Substances Act by adding 21 U.S.C. § 802(16)(B), which excludes hemp from the definition of marijuana. This exclusion applies only to "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The statutory language "all derivatives, extracts, cannabinoids, isomers" has become the central point of legal contention. Hemp industry lawyers argue this phrase encompasses delta-8 THC, delta-10 THC, HHC, THC-O, and other cannabinoids derived from legal hemp. The DEA counters that the Interim Final Rule's definition of "synthetically derived tetrahydrocannabinols" in 21 CFR § 1308.11(d)(31) excludes chemically converted cannabinoids from the hemp exemption. No federal court has definitively resolved this question. The closest case, AK Futures LLC v. Boyd Street Distro LLC, a trademark dispute in the Central District of California, included dicta suggesting delta-8 THC derived from hemp falls within the 2018 Farm Bill's scope, but the court did not rule on the Controlled Substances Act question. The Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 301 et seq., grants the FDA authority over foods, drugs, dietary supplements, and cosmetics. Section 331(ll) prohibits introducing into interstate commerce any food containing a drug active ingredient, which the FDA interprets to include CBD and other cannabinoids. However, the FDA has exercised enforcement discretion, issuing warning letters for egregious violations but not systematically removing hemp-derived products from the market. The Agricultural Marketing Act of 1946, as amended by the 2018 Farm Bill, requires the USDA to establish a regulatory framework for hemp production. The USDA's final rule, published in the Federal Register on January 19, 2021 (86 FR 5596), establishes testing protocols, sampling procedures, and compliance requirements for hemp cultivation. The rule measures only delta-9 THC concentration and does not address THCA or other cannabinoids, creating the THCA flower loophole. Section 10114 of the 2018 Farm Bill prohibits states from restricting interstate transportation or shipment of hemp or hemp products lawfully produced under a state or tribal plan. This preemption clause has been interpreted to prevent states from blocking hemp commerce, though states retain police powers to regulate sales within their borders.

State-by-State Breakdown

State approaches to hemp-derived THC range from complete prohibition to regulated markets to unregulated free-for-all, creating a complex compliance landscape for interstate commerce.

California

California enacted Assembly Bill 45 in October 2023, establishing a regulatory framework for hemp-derived cannabinoid products. The law caps delta-9 THC at 0.3% by weight for raw plant material and 0.5 mg per serving for edibles. THCA flower remains legal but must comply with testing, labeling, and packaging requirements identical to those for licensed marijuana products. Sales are restricted to individuals 21 and older. The California Department of Public Health began enforcing these rules in July 2024, issuing cease-and-desist letters to retailers selling non-compliant products.

Colorado

Colorado banned delta-8 THC and other hemp-derived intoxicants in July 2021 through emergency rulemaking by the Colorado Department of Public Health and Environment. The state defines total THC (delta-9 THC plus THCA multiplied by 0.877) as the regulatory metric, effectively prohibiting THCA flower. Possession and sale of these products constitute criminal violations. Colorado's approach reflects the state's mature licensed marijuana market and concerns about unregulated competition.

Florida

Florida allows hemp-derived THC products with minimal restrictions. The state's hemp program, administered by the Florida Department of Agriculture and Consumer Services, follows the federal 0.3% delta-9 THC threshold without addressing THCA or delta-8. Retailers sell THCA flower, delta-8 gummies, and THC beverages alongside CBD products with no age restrictions or testing requirements beyond basic hemp compliance. This permissive environment has made Florida the largest hemp-derived THC market, with estimated 2025 sales of $4.2 billion.

Georgia

Georgia permits hemp-derived cannabinoid products under the Georgia Hemp Farming Act, passed in 2019. The law caps THC at 5 mg per package for edibles and requires products to be derived from hemp grown under a licensed program. THCA flower exists in a gray area—technically legal under the statute but facing potential enforcement by local prosecutors. Atlanta and Athens have seen proliferation of THCA flower retailers, while rural counties have prosecuted sellers under marijuana laws.

Minnesota

Minnesota enacted comprehensive hemp-derived cannabinoid regulations in July 2023 through House File 3595. The law establishes a tiered system: edible products may contain up to 5 mg THC per serving and 50 mg per package; beverages may contain up to 5 mg per container. THCA flower is prohibited. Products must undergo third-party testing for potency, pesticides, heavy metals, and microbial contaminants. The Minnesota Department of Health licenses manufacturers and retailers, creating a mini-regulatory system parallel to the state's medical marijuana program. Sales are restricted to individuals 21 and older.

New York

New York initially banned delta-8 THC in 2021 but reversed course in 2023 with the Cannabis Law's hemp provisions. The state now allows hemp-derived cannabinoid products containing up to 0.3% delta-9 THC by weight, with no restrictions on THCA. However, products must be sold through licensed retailers registered with the New York State Office of Cannabis Management. This licensing requirement has limited market growth, as many hemp retailers have not pursued registration. Unlicensed sales continue in smoke shops and bodegas despite state enforcement efforts.

Ohio

Ohio legalized adult-use marijuana through a ballot initiative in November 2023, with sales beginning in August 2024. The state simultaneously enacted hemp-derived cannabinoid regulations capping delta-9 THC at 2 mg per package for edibles. THCA flower remains legal under the state's hemp program administered by the Ohio Department of Agriculture. The dual market has created confusion, with THCA flower selling for $50-80 per ounce compared to $200-300 per ounce for licensed marijuana.

Texas

Texas maintains a permissive stance on hemp-derived THC despite marijuana prohibition. The state's hemp program, established by House Bill 1325 in 2019, follows the federal 0.3% delta-9 THC definition. Delta-8 THC and THCA flower are widely available in smoke shops, gas stations, and online retailers. The Texas Department of State Health Services attempted to ban delta-8 in 2021, but a state district court issued a temporary injunction blocking enforcement. The case remains in litigation as of May 2026, with delta-8 sales continuing during the legal dispute.

Market and Business Implications

The hemp-derived THC market has created a parallel cannabis economy operating outside state-licensed systems, generating billions in revenue but facing existential regulatory risk. Industry analysts estimate total hemp-derived THC sales reached $28 billion in 2025, including $8 billion in THCA flower, $12 billion in delta-8 and delta-9 edibles, $5 billion in vape products, and $3 billion in beverages and tinctures. This figure represents approximately 40% of the $70 billion total U.S. cannabis market, including both legal and illicit sales. The hemp THC supply chain differs fundamentally from licensed marijuana. Cultivators grow high-CBD or high-THCA hemp under USDA-approved state plans, harvesting biomass that sells for $300-500 per pound compared to $1,000-2,000 per pound for licensed marijuana. Processors extract cannabinoids and either sell crude oil to manufacturers or convert CBD to delta-8 THC through isomerization. Finished products reach consumers through smoke shops, gas stations, online retailers, and convenience stores—distribution channels unavailable to licensed marijuana businesses. This business model offers significant advantages. Hemp businesses deduct normal business expenses on federal tax returns, while marijuana companies face effective tax rates of 70% or higher under Section 280E of the Internal Revenue Code. Hemp products ship via USPS, UPS, and FedEx, while marijuana cannot cross state lines. Hemp retailers avoid the $50,000-500,000 licensing fees required for marijuana dispensaries. Multi-state operators have responded to hemp competition with mixed strategies. Some, like Curaleaf and Trulieve, have launched hemp-derived product lines to capture market share while advocating for federal restrictions. Others, like Green Thumb Industries, have avoided the hemp market entirely and lobbied for enforcement against what they characterize as "synthetic" products. Investment capital has flowed into hemp-derived cannabinoids despite regulatory uncertainty. Private equity firms invested an estimated $2.1 billion in hemp THC companies in 2024 and 2025 combined, according to data from Viridian Capital Advisors. These investments carry significant risk—a federal crackdown or restrictive Farm Bill amendment could render entire product lines illegal overnight. The proposed Republican amendments would reshape the market by establishing federal standards. A 5 mg per serving cap on edibles would align hemp products with limits in states like Minnesota and California, potentially reducing potency for some existing products. Third-party testing requirements would increase costs by an estimated $500-1,500 per batch, according to hemp industry consultants. Age restrictions would eliminate gas station and convenience store sales to minors, a practice that has drawn criticism from public health advocates. Conversely, federal standards would provide legal certainty that could accelerate institutional investment and mainstream retail adoption. Payment processors like Visa and Mastercard have restricted hemp THC transactions due to legal ambiguity; clear federal rules could open traditional banking and credit card processing.

What Experts Say

Legal scholars, industry representatives, and public health experts offer sharply divergent views on how federal law should address hemp-derived THC products. According to Robert Mikos, a cannabis law professor at Vanderbilt Law School, the 2018 Farm Bill's language creates a genuine legal ambiguity. In a February 2025 law review article, Mikos wrote that the statute's phrase "all derivatives, extracts, cannabinoids, isomers" of hemp could reasonably be interpreted to include delta-8 THC, but the DEA's synthetic cannabinoid rule also has statutory support. Mikos argues Congress must clarify its intent through new legislation rather than leaving the question to agency interpretation or courts. Jonathan Miller of the U.S. Hemp Roundtable has stated that the industry supports federal regulation but opposes prohibition. In testimony before the House Agriculture Committee in March 2026, Miller said the hemp industry has proposed a framework including potency limits, age restrictions, testing requirements, and labeling standards that would address safety concerns while preserving legal commerce. Miller emphasized that hemp-derived products serve consumers in prohibition states who lack access to licensed marijuana. Diane Czarkowski of the Cannabis Trade Federation argues that intoxicating hemp products undermine state regulatory systems and create public health risks. In an April 2026 interview with MJBizDaily, Czarkowski said that delta-8 and THCA products often contain contaminants including residual solvents, pesticides, and heavy metals because they are not subject to the rigorous testing required for licensed marijuana. She called for federal action to close the hemp loophole and protect consumers. Dr. Ryan Vandrey, a cannabis researcher at Johns Hopkins University, has expressed concern about the lack of research on delta-8 THC and other semi-synthetic cannabinoids. In a 2024 study published in the Journal of Cannabis Research, Vandrey's team found that commercially available delta-8 products often contain unlabeled delta-9 THC, delta-10 THC, and unknown compounds formed during the isomerization process. Vandrey told the Washington Post in January 2025 that consumers are "essentially participating in an uncontrolled chemistry experiment" when using these products. Paul Armentano, deputy director of NORML, has argued that hemp-derived THC products demonstrate the failure of marijuana prohibition. In a March 2026 blog post, Armentano wrote that the hemp loophole exists because Congress legalized one form of cannabis while maintaining criminal penalties for another chemically identical plant. He advocates for comprehensive marijuana legalization rather than restricting hemp products. State regulators have called for federal leadership. Andrew Freedman, former director of marijuana coordination for Colorado, told a Senate committee in February 2025 that the patchwork of state hemp laws creates impossible compliance burdens for interstate commerce and that only federal standards can resolve the regulatory chaos.

What's Next

The 2025 Farm Bill debate will determine whether hemp-derived THC products remain legal, with key decisions expected between June and September 2026. The House Agriculture Committee is scheduled to mark up the 2025 Farm Bill in June 2026. The Republican amendments proposed by Representatives Massie and Mace will face opposition from members representing states with licensed marijuana markets, including Representatives Barbara Lee of California and Earl Blumenauer of Oregon. The committee vote will indicate whether a regulatory compromise can advance or whether hemp THC provisions will be stripped from the bill. If the House passes a Farm Bill with hemp THC provisions, the Senate must reconcile its version. Senate Agriculture Committee Chair John Boozman of Arkansas has not publicly stated his position on hemp-derived intoxicants, making the Senate's approach uncertain. A conference committee would resolve differences between House and Senate versions, with final passage unlikely before September 2026. Absent congressional action, the DEA could pursue enforcement through administrative rulemaking. The agency could issue a final rule clarifying that all chemically converted THC isomers constitute synthetic controlled substances, effectively banning delta-8 and similar products. Such a rule would face legal challenges from industry groups arguing the DEA exceeded its statutory authority. States will continue enacting their own regulations regardless of federal action. Legislatures in Alabama, Indiana, and South Carolina are considering hemp THC bills in 2026 sessions. These state-level developments will further fragment the regulatory landscape. The FDA has indicated it may seek additional congressional authority to regulate hemp-derived products. In a May 2025 statement, FDA Commissioner Robert Califf said the agency needs "clear statutory authority and adequate resources" to oversee the hemp cannabinoid market. Any FDA regulatory framework would likely focus on product safety, labeling, and manufacturing standards rather than prohibition. Industry consolidation is expected to accelerate. Smaller hemp THC companies face increasing compliance costs and legal uncertainty, making them acquisition targets for larger CBD companies or multi-state marijuana operators hedging their bets. Mergers and acquisitions in the hemp sector totaled $890 million in 2025, a figure analysts expect to exceed $1.5 billion in 2026. Consumer behavior will shift based on regulatory outcomes. If federal restrictions eliminate high-potency THCA flower and delta-8 products, some consumers will migrate to licensed marijuana markets in legal states, while others may return to illicit sources. Public health researchers will monitor youth access, impaired driving incidents, and poison control calls to assess the impact of any regulatory changes.

Further Reading

• Agriculture Improvement Act of 2018 (2018 Farm Bill), Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• DEA Interim Final Rule, Implementation of the Agriculture Improvement Act of 2018, 85 FR 51639 (August 21, 2020), available at https://www.federalregister.gov/documents/2020/08/21/2020-18455/implementation-of-the-agriculture-improvement-act-of-2018
• USDA Final Rule, Establishment of a Domestic Hemp Production Program, 86 FR 5596 (January 19, 2021), available at https://www.federalregister.gov/documents/2021/01/19/2021-00967/establishment-of-a-domestic-hemp-production-program
• U.S. Hemp Roundtable policy positions and regulatory proposals, available at https://www.hempsupporter.com
• FDA Report to Congress on Hemp and Hemp-Derived Compounds (May 2024), available at https://www.fda.gov/news-events/congressional-testimony/hemp-production-and-2018-farm-bill-07252019
• Controlled Substances Act, 21 U.S.C. § 801 et seq., full text available at https://uscode.house.gov/view.xhtml?path=/prelim@title21/chapter13&edition=prelim
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., full text available at https://uscode.house.gov/view.xhtml?path=/prelim@title21/chapter9&edition=prelim
• Minnesota hemp-derived cannabinoid regulations, House File 3595 (2023), available at https://www.revisor.mn.gov/bills/bill.php?b=House&f=HF3595&ssn=0&y=2023
• California Assembly Bill 45 (2023), hemp-derived cannabinoid framework, available at https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240AB45
• Vandrey et al., "Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products," Journal of Cannabis Research (2024), available at https://jcannabisresearch.biomedcentral.com